Terns Pharmaceuticals, Inc. ( (TERN) ) has released its Q2 earnings. Here is a breakdown of the information Terns Pharmaceuticals, Inc. presented to its investors.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing small-molecule product candidates to address serious diseases, particularly in the fields of oncology and obesity.
In its latest earnings report for the second quarter of 2025, Terns Pharmaceuticals highlighted significant progress in its clinical trials, notably the Phase 1 trial of TERN-701 for chronic myeloid leukemia (CML) and the Phase 2 trial of TERN-601 for obesity. The company also reported a strong cash position expected to support operations into 2028.
Key financial metrics from the report include a net loss of $24.1 million for the quarter, compared to $22.7 million in the same period last year. Research and development expenses increased to $20.4 million, reflecting the company’s ongoing investment in its clinical programs. Terns Pharmaceuticals is advancing its CML program and seeking partnerships for its metabolic assets.
The company is optimistic about the upcoming data readouts from its ongoing trials, which are expected to provide insights into the efficacy and safety of its product candidates. Terns Pharmaceuticals is particularly focused on advancing TERN-701 towards a pivotal trial, aiming to offer a potentially best-in-class therapy for CML.
Looking ahead, Terns Pharmaceuticals remains committed to executing its strategic plans, with a focus on oncology and potential partnerships to further develop its metabolic programs. The company’s management is confident in its ability to achieve key milestones and continue its clinical advancements.